Troubling New Research on MRSA in Kids

New Research Estimates MRSA Infections Cost U.S. Hospitals $3.2 Billion to $4.2 Billion Annually

The annual nationwide cost to treat hospitalized patients with methicillin-resistantStaphylococcus aureus (MRSA) infections is estimated to be between $3.2 billion to $4.2 billion, according to a new analysis presented at the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). The high costs of treating infections caused by MRSA, a serious, multi-drug resistant-pathogen, are primarily driven by prolonged hospital stays, including time spent in intensive care units.(1)  Previous data showed that patients with MRSA infections may be in the hospital 10 days longer than patients with Staph infections not resistant to methicillin.

“MRSA is acknowledged as a growing problem, but the associated medical costs are not well documented.  This research helps to quantify the significant economic burden of MRSA to U.S. hospitals,” says Larry Liu, MD, PhD, lead investigator and director of U.S. Outcomes Research Group at Pfizer Inc.  “Strategies to minimize hospital costs related to MRSA infections need to be considered to help manage this burden.”

MRSA infections are rising in hospitals and long-term care facilities and also have increasingly been found in the community.  MRSA infections are difficult to treat because they are resistant to several commonly used antibiotics, including penicillin containing antibiotics, and are associated with significant morbidity and mortality.  In intensive care units, physicians are now seeing infection rates of approximately 60 percent due to MRSA.  Each year, 90,000 patients die as a result of a hospital-acquired infection, including those caused by MRSA.

Methicillin-resistant Staphylococcus aureus (MRSA) is a topic of increasing concern in the realm of healthcare. MRSA was one of the first bacteria to develop resistance to drugs. S. aureus is actually present in abundance in the human body, but when introduced to an immunocompromised patient, it can be very severe. Because of this, MRSA can be particularly alarming in hospital and healthcare settings, resulting in longer hospital stays, more expensive, less effective, and possibly more toxic treatments, and even death. According to the Centers for Disease Control, in 1974 MRSA accounted for 2% of staph infections; by 1995 that number had increased to 22%, and in 2004, it was a whopping 63%.

For several years, health professionals have been concerned about the rise in infections from methicillin resistant staphylococcus aureus, or MRSA – a bacteria that’s resistant to several of the antibiotics generally used to treat staph infections. CDC estimates that in 2005, there were more than 94,000 MRSA infections in the US, and more than 18,000 of those patients died. The numbers are probably much higher now.

A study just published in the journal Pediatrics gives us new information about staph infections in hospitalized US children and how they’re being treated. The results show a disturbing increase in the number of MRSA cases, and suggest that we might be creating conditions that’ll encourage the bacteria to evolve further resistance and become an even greater threat.

The researchers – Joshua C. Herigon, Adam L. Hersh, Jeffrey S. Gerber, Theoklis E. Zaoutis and Jason G. Newland – analyzed data about patients under the age of 18 who were admitted to a hospital and diagnosed with an Staphylococcus aureus infection from 1999 – 2008. The data came from the Pediatric Health Information System database maintained by a collaborative of not-for-profit, tertiary care pediatric hospitals from across the US, and the researchers used data from the 25 hospitals that had submitted complete data for the study period.

The researchers examined 2.4 million patient discharges and found that 3% of the children had been diagnosed with S aureus infections, and the most common infection type (39%) was skin and soft tissue infections. The most striking finding has to do with the incidence rate (emphasis added):

During the 10-year study period, the incidence of S aureus infection more than doubled, increasing from 14.8 per 1000 admissions in 1999 to 35.7 per 1000 admissions in 2008 … The incidence of MRSA infections during this period increased 10-fold, from 2.0 cases per 1000 admissions in 1999 to 20.7 cases per 1000 admissions in 2008.

How Does NutraSilver Compare to Traditional Antibiotic MRSADisease Treatments?

Unlike antibiotics, NutraSilver kills viruses, bacteria and fungal infections. There are no known side effects using NutraSilver other than taking too much too fast (healing crisis). None of the traditional side effects of using traditional antibiotics exists using NutraSilver. NutraSilver® can be a safe, effective and comfortable experience eliminating MRSA from the body without allergic reactions or any other life-threatening side effects known to exist using current antibiotics therapies. Find out more about how to protect yourself from MRSA.



About CareMan
I am the CareMan, have been for 7 years now. I really do care about YOU and getting YOU back to great, natural health, so long as you have an open mind.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: